Lb Pharmaceuticals (LBRX) Return on Equity (2025 - 2026)

Lb Pharmaceuticals (LBRX) recorded quarterly Return on Equity of 0.0% in Q1 2026, down 39.43% quarter-over-quarter from 0.0% in Q4 2025.

Lb Pharmaceuticals (LBRX) Return on Equity (2025 - 2026) Analysis & Trends

Lb Pharmaceuticals' Return on Equity history runs 2 years deep, the most recent figure standing at 0.0% for Q1 2026.

In Q1 2026, Return on Equity changed N/A year-over-year to 0.0%; the TTM figure through Mar 2026 stood at 0.0% (changed N/A YoY), while the FY2025 annual figure was 0.0%, changed N/A from the prior year.
Return on Equity was 0.0% for Q1 2026 at Lb Pharmaceuticals, down from 0.0% in the prior quarter.
In the past five years, Return on Equity ranged from a high of 0.0% in Q4 2025 to a low of 0.0% in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROE (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-0.81%
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-0.04%
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	0.00%
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-0.01%
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	0.00%
9	Abivax	91.96 Bn	91.96 Bn	-	-0.01%
10	Lb Pharmaceuticals	843.30 Mn	843.30 Mn	-	0.00%

Download Data